ATRA News and Press, Atara Biotherapeutics Inc. From 07/24/25

2025-07-24 10:49:03 ET More on Atara Biotherapeutics Atara gains after insider purchase Atara Biotherapeutics prices $16M public offering Seeking Alpha’s Quant Rating on Atara Biotherapeutics Historical earnings data for Atara Biotherapeutics F...

Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) PR Newswire First allogeneic T-C...

2025-07-22 15:02:37 ET More on Atara Biotherapeutics Atara Biotherapeutics prices $16M public offering Atara Biotherapeutics to reduce workforce by 30% Seeking Alpha’s Quant Rating on Atara Biotherapeutics Historical earnings data for Atara Biotherapeu...

Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc. PR Newswire Pierre Fabre Laboratories is now responsible for all global clinical trial activities for the tabelecleucel clinical prog...

Atara Biotherapeutics Resubmits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease to the U.S. FDA Approval of BLA Would Trigger $40 Million Milestone Payment from Pierre Fabre Laboratories ...

2025-05-16 21:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, announced the appointment of James Huang and Nachi Subramani...

2025-05-15 08:56:20 ET More on Atara Biotherapeutics Atara Biotherapeutics prices $16M public offering Atara Biotherapeutics to reduce workforce by 30% Seeking Alpha’s Quant Rating on Atara Biotherapeutics Historical earnings data for Atara Biotherapeu...

2025-05-15 08:42:01 ET More on Atara Biotherapeutics Atara Biotherapeutics to reduce workforce by 30% Seeking Alpha’s Quant Rating on Atara Biotherapeutics Historical earnings data for Atara Biotherapeutics Financial information for Atara Biotherapeuti...

Atara has transferred all manufacturing responsibility to Pierre Fabre Laboratories, including all costs associated with the manufacturing and supply of tabelecleucel for development and commercialization worldwide Atara expects to reduce its operating expenses year-over-year by approxima...